Keystone Symposia

Fairmont Château Laurier Floorplan

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2012

Here are the related meetings in 2020:
MEETING CANCELLED: Transforming Vaccinology (L2)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Immunological Mechanisms of Vaccination (S3)

Organizer(s) Adrian V.S. Hill, Dan H. Barouch, John T. Harty and Tania H. Watts
December 13—18, 2012
Fairmont Château Laurier • Ottawa, ON Canada
Abstract Deadline: Aug 13, 2012
Late Abstract Deadline: Sep 13, 2012
Scholarship Deadline: Aug 13, 2012
Early Registration Deadline: Oct 11, 2012

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Summary of Meeting:
Vaccines are remarkably successful in reducing morbidity and mortality from infectious diseases in both developed and developing countries. However, globally, mortality from infectious disease still exceeds 10 million deaths annually, reflecting a need for new, more effective and more deployable vaccination approaches. As many of the relatively easy vaccines have already been made, vaccinology is now tackling more difficult diseases, often caused by complex and genetically variable pathogens. A better understanding of the immunological mechanisms underpinning existing and novel vaccines is therefore required. Fortunately, research efforts to uncover new molecular and cellular techniques offer exceptional opportunities for improved vaccine design. A better understanding of the immunology of vaccination will be of value in evidence-based design of new vaccines against major global causes of mortality such as HIV, malaria and tuberculosis, and against emerging infections such as swine influenza and dengue. Advances in immunology, genomics and systems biology are beginning to offer a deeper understanding of the molecular and cellular mechanisms of host immunity, and the pivotal role played by the innate immune system in shaping the adaptive immune response. This is providing new opportunities to identify new signatures of vaccine immunogenicity and protective efficacy, which should facilitate vaccine development and guide improved vaccine design. The Keystone Symposia meeting on Immunological Mechanisms of Vaccination will bring together an interdisciplinary group of scientists in vaccinology, immunology and pathogen biology, to address recent advances in these fields and their potential for accelerating vaccine design and development.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


Arrival and Registration

Main Lobby
Welcome and Keynote Address (Joint with Grand Challenges Meeting)

Canada Hall 1, Ottawa Convention Centre
* Christopher L. Karp, Bill & Melinda Gates Foundation, USA

Chris Wilson, Bill & Melinda Gates Foundation, USA
Translating Immunology into Vaccinology

Bruce A. Beutler, University of Texas Southwestern Medical Center, USA
Genetics and Innate Immunity

Social Hour with Lite Bites

Trillium Ballroom, Ottawa Convention Centre



Adam/Drawing Rooms
Innate Sensing of Pathogens and Vaccines

* Julie Magarian Blander, Weill Cornell Medicine, Cornell University, USA

Stephanie C. Eisenbarth, Yale University, USA
NLR Regulation of Dendritic Cell Priming during Immunization

Yan Shi, University of Calgary, Canada
Immune Activation by Force

Dana Philpott, University of Toronto, Canada
Nod Proteins: Regulators of Inflammation and Autophagy

William R. Heath, University of Melbourne
Dendritic Cell Receptors and T Cell Induction

Nicolas Chevrier, Harvard University, USA
Short Talk: System-Level Analysis of the Toll-Like Receptor Network Delineates Viral and Inflammatory Sensing Circuits

Taryn L. Osmond, Malaghan Institute of Medical Research, New Zealand
Short Talk: Splenic CD8alpha+Langerin+ Dendritic Cells: Firing up the Immune Environment for CD8+ T Cell Responses

Coffee Break

Adam/Drawing Rooms
Poster Setup

Adam/Drawing Rooms
On Own for Lunch and Recreation

Poster Viewing

Adam/Drawing Rooms
Workshop 1: Novel Adjuvants

* Katrina D. Gee, Queen's University, Canada

* Sam Basta, Queen's University, Canada

Frank Wegmann, Janssen, Netherlands
Polyethyleneimine is a Potent Mucosal Adjuvant for Glycoproteins with Innate and Adaptive Immune Activating Properties

Sang Mu Shim, Korea Research Institute of Bioscience and Biotechnology (KRIBB), South Korea
Poly gamma Glutamic Acid-Chitosan Nanogel Dramatically Enhance the Efficacy of Pandemic H1N1 Influenza Vaccine

Thomas W. Dubensky, Jr., Tempest Therapeutics, USA
Development of Cyclic Dinucleotides (CDNs) as STING-Targeted Molecular Adjuvants

Karen Smith Korsholm, Statens Serum Institut, Denmark
The Effect of the Immunostimulating Glycolipid MMG in Cationic Liposomal Vaccine Adjuvants

Silvia Vendetti, Istituto Superiore di Sanità, Italy
Achieving Mucosal and Systemic Immunity by Exploiting Vitamin A Metabolites as Vaccine Co-Adjuvants

Esteban Celis, Moffitt Cancer Center, USA
BiVax: A Peptide/Poly-IC Subunit Vaccine that Mimics an Acute Infection Elicits Vast and Effective Anti-Tumor CD8 T Cell Responses

Maria L. Knudsen, Fred Hutchinson Cancer Research Center, USA
Alphavirus Replicons Encoding the TLR5 Ligand Flagellin is a Potent Adjuvant for IgG Response

Coffee Available

Adam/Drawing Rooms
Augmenting Immune Responses to Vaccines

* Dan H. Barouch, Beth Israel Deaconess Medical Center, USA

Robert A. Seder, NIAID, National Institutes of Health, USA
Differential Effects of Innate Immunity and Antigen Load on CD8 T Cell Immunity Following Viral Vaccination

Tania H. Watts, University of Toronto, Canada
CD137L (4-1BBL) as an Immune Stimulant in Acute and Chronic Viral Infections

Rafick Sekaly, Case Western Reserve University, USA
Systems Biology Approaches Show the Impact of Ethnic Groups on Innate and Adaptive Characteristics that Correlate with Protective Immune Responses to the Yellow Fever Vaccine

Daniel D. Pinschewer, University of Geneva, Switzerland
LCMV-Based Vaccine Vectors: Viral Immunobiology Teaches Vaccinology

Nicolas Cuburu, NIH, National Cancer Institute, USA
Short Talk: Prime/Boost Genital Immunization with Human Papillomaviral Vectors Preferentially Induces CD103+CD8+ Tissue Resident Memory Cells in the Mouse Female Genital Tract

Social Hour with Lite Bites

Adam/Drawing Rooms
Poster Session 1

Adam/Drawing Rooms



Adam/Drawing Rooms
Poster Setup

Adam/Drawing Rooms
Poster Viewing

Adam/Drawing Rooms
T Cell Memory to Vaccines

* Nathalie Labrecque, Maisonneuve-Rosemont Hospital Research Centre, Canada

* Susan M. Kaech, The Salk Institute, USA

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Technologies for Tracking T Cell Responses

John T. Harty, University of Iowa, USA
Alternative Strategies for Generating Protective Numbers of Memory CD8 T Cells by Prime-Boost Immunization

Ross M. Kedl, University of Colorado Denver, USA
Short Talk: Antigen Persistence after Subunit Vaccination Correlates with the Generation and Maintenance of Protective Cellular Immunity

Marc K. Jenkins, University of Minnesota Medical School, USA
Origins of CD4+ Memory T Cells

David B. Masopust, University of Minnesota, USA
CD8 T Cell Memory Induced by Heterologous Prime-Boost Vaccination

Cara Skon, Genentech, Inc., USA
Short Talk: Transcriptional Downregulation of S1PR1 is Required for Establishment of Resident Memory CD8 T Cells

Coffee Break

Adam/Drawing Rooms

Adam/Drawing Rooms
Poster Session 2

Adam/Drawing Rooms
Coffee Available

Adam/Drawing Rooms
B Cell Memory to Vaccines

* Jamie K. Scott, Simon Fraser University, Canada

* Richard A. Kroczek, Robert Koch-Institute, Germany

Bonnie B. Blomberg, University of Miami School of Medicine, USA
Biomaker and Molecular Mechanisms for Human B cell and Antibody Responsiveness to Vaccines

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
Human Antibody Responses to HIV

Shane Crotty, La Jolla Institute for Immunology, USA
Tfh Cells: Providing T Cell Help for B Cell Responses

Peter Sage, Harvard Medical School, USA
Short Talk: PD-1 Controls Lymph Node and Blood T Follicular Regulatory Cells

On Own for Dinner



Adam/Drawing Rooms
Understanding Signatures of Vaccine Protective Efficacy

* Bonnie B. Blomberg, University of Miami School of Medicine, USA

* Vladimir Badovinac, University of Iowa, USA

Bali Pulendran, Stanford University School of Medicine, USA
Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology

Ennio De Gregorio, GlaxoSmithKline Vaccines, Italy
Immune Profiling of Vaccine Adjuvants

Susan M. Kaech, The Salk Institute, USA
Regulation or Antiviral Immunity by PGE-2 During Chronic Viral Infection

Willem A. Hanekom, Bill & Melinda Gates Foundation, USA
Human Gene Expression Signatures of Risk of Tuberculosis Disease

Magali Matsumiya, University of Oxford, UK
Short Talk: Predicting the Immune Response to MVA85A

Coffee Break

Adam/Drawing Rooms
Poster Setup

Adam/Drawing Rooms
On Own for Lunch and Recreation

Poster Viewing

Adam/Drawing Rooms
Workshop 2: Vaccine Delivery

* Adrian V. S. Hill, Jenner Institute, University of Oxford, UK

Peter Lauer, Aduro BioTech, Inc., USA
Recombinase-Induced Intracellular Death (Lm-RIID): A Novel, Safe, and Potent L. Monocytogenes Vaccine Platform

Ana Carolina dos Reis Albuquerque Cajaraville, Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos, Brazil
Characterization of a Malaria Vaccine Candidate Based in the Yellow Fever 17D Virus Vector

Matthew D. J. Dicks, University of Oxford, UK
Why Are Some Adenovirus Vaccine Vectors More Immunogenic Than Others?

* Allan Randrup Thomsen, University of Copenhagen, Denmark
Generation of Transgene-Specific CD8 T Cells by Immunization with Adenoviral Vectors Is Markedly Augmented by Co-Expression of Transgene and IL-2 in the Same Vector

Torben Knuschke, University of Duisburg-Essen, Germany
Biodegradable Calcium Phosphate Nanoparticles: A New Conjugated Vaccine Approach for Prophylactic and Therapeutic Anti-Viral Treatment

Masaru Kanekiyo, NIAID, National Institutes of Health, USA
A Self-Assembling Influenza Nanoparticle Vaccine Elicits Broad and Potent Neutralizing Antibodies

Even Fossum, Institute of Immunology, Norway
Vaccines Designed to Specifically Target Cross-Presenting DCs

Shaomin Tian, University of North Carolina at Chapel Hill, USA
Rational Design of PRINT Nano-Vaccines

Coffee Available

Adam/Drawing Rooms
Translating Immunity to Vaccines

* Tania H. Watts, University of Toronto, Canada

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Novel HIV Vaccine Strategies

Helen McShane, Jenner Institute, UK
Clinical Development of TB Vaccines

Daniela Weiskopf, La Jolla Institute for Immunology, USA
Short Talk: Comprehensive Analysis of Dengue Virus-Specific Responses Supports an HLA-Linked Protective Role for CD8+ T Cells, Rather Than a Pathogenic Role Linked to Original Antigenic Sin

Ma Luo, University of Manitoba, Canada
Short Talk: Antibody and T Cell Response to the Protease Cleavage Sites Correlated with Protection Against Higher Dose of SIVmac239 Challenge and Disease Progression in Cynomolgus Macaques

Bram Slütter, University of Iowa, USA
Short Talk: CXCR3+ Memory CD8+ T Cells Localize to the Respiratory Tract and Provide Superior Protection Against Influenza A Virus

Social Hour with Lite Bites

Adam/Drawing Rooms
Poster Session 3

Adam/Drawing Rooms



Adam/Drawing Rooms
Immunity and Vaccines Against Global Threats I

* John T. Harty, University of Iowa, USA

* Helen McShane, Jenner Institute, UK

Adrian V. S. Hill, Jenner Institute, University of Oxford, UK
Generating Unnatural Immunity

Rafi Ahmed, Emory University School of Medicine, USA
Human B Cell Response to Influenza Virus

Dennis L. Kasper, Harvard Medical School, USA
Rethinking Glycocojugate Vaccines: A Knowledge-Based Approach to Vaccine Design

Claire A. Jones, University of Oxford, UK
Short Talk: Quantification of Antibody Secreting Cell Responses in a Human Model of Salmonella typhi Infection

Mark Y. Sangster, University of Rochester, USA
Short Talk: The B Cell Response to an Inactivated Pandemic H1N1 Influenza Vaccine in Cohorts Differing by Age and Immune Status

David Furman, Buck Institute for Research on Aging, USA
Short Talk: Robust Correlates of an Immune Response to Influenza Vaccination in Young and Old Adults

Coffee Break

Adam/Drawing Rooms
On Own for Lunch and Recreation

Coffee Available

Adam/Drawing Rooms
Immunity and Vaccines Against Global Threats II

* Adrian V. S. Hill, Jenner Institute, University of Oxford, UK

* Alessandro Sette, La Jolla Institute for Allergy & Immunology, USA

Dany De Grave, Sanofi Pasteur, USA
The Sanofi Pasteur Tetravalent Dengue Vaccine: An Update

Louis J. Picker, Oregon Health & Science University, USA
Unique Immunobiology and Efficacy of SIV Protein-Expressing Cytomegalovirus (CMV) Vectors

Jerald C. Sadoff, Crucell Vaccine Institute, Janssen Pharmaceutical Companies of Johnson & Johnson, Netherlands
Vaccine Vectors for HIV and Other Global Threats

David M. Lewinsohn, Oregon Health & Science University, USA
Short Talk: Lessons from a Human Phase I Trial: Vaccination with the Mtb Vaccine AERAS-402 (BCG Prime / Adenoviral Boost) Induces High Frequency, Antigen-Specific CD8 T Cells That Do Not Necessarily Recognize the Mtb-Infected Cell

Social Hour with Lite Bites

Adam/Drawing Rooms

Adam Room



*Session Chair †Invited, not yet responded.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health

Grant No. 1R13AI102519-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional support for this conference from:

Biogen Idec

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novartis Vaccines and Diagnostics

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email:,
Phone:+1 970-262-1179